Phase 2 study of TLK286 [canfosfamide; TELCYTA; Telik] administered weekly in advanced non-small cell lung cancer.
Phase of Trial: Phase II
Latest Information Update: 16 Jun 2011
At a glance
- Drugs Canfosfamide (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 14 Jan 2008 Status change from in progress to completed.
- 15 Oct 2007 Clinical hold removed by FDA - status changed from suspended to in progress.
- 04 Jun 2007 Status change from in progress to suspended - FDA clinical hold